Conatus Pharmaceuticals Inc. 4
4 · Conatus Pharmaceuticals Inc. · Filed Feb 8, 2016
Insider Transaction Report
Form 4
Hagerty David T
EVP, Clinical Development
Transactions
- Award
Stock Option (Right to Buy)
2016-02-04+109,375→ 109,375 totalExercise: $1.85Exp: 2026-02-03→ Common Stock (109,375 underlying) - Award
Stock Option (Right to Buy)
2016-02-04+21,875→ 21,875 totalExercise: $1.85Exp: 2026-02-03→ Common Stock (21,875 underlying)
Footnotes (2)
- [F1]The option was granted on February 4, 2016. 25% of the total number of shares of common stock subject to the option will vest on February 4, 2017, and 1/48th of the total number of shares of common stock subject to the option will vest monthly thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date.
- [F2]The Reporting Person was granted a performance based option on February 4, 2016 that will vest, subject to the Reporting Person's continued employment or service relationship with the Issuer through the applicable vesting date, upon the achievement of certain performance conditions, as approved by the Issuer's compensation committee.